Lobular Breast Cancer Alliance (LBCA) Scientific Advisory Board Chair and Dana Farber Oncologist Dr. Rinath Jeselsohn recently talked to LBCA's Executive Director Laurie Hutcheson about her latest invasive lobular carcinoma (ILC) study "A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer." The study's goal was to better understand the unique features of the estrogen receptor in lobular breast cancer. In particular, she sought to investigate what role the protein FOXA1 may play in limiting the effectiveness of Tamoxifen in repressing ILC tumor growth.
PLEASE NOTE: We are not able to respond to individual questions about this post.